Eli Lilly (LLY)
1,409.38
-1.61 (-0.11%)
NYSE · Last Trade: Nov 4th, 12:46 AM EST
News & Press Releases
What to expect from ANI Pharmaceuticals’s (ANIP) Q3 earnings
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Thursday before market open. Here’s what investors should ...
Via StockStory · November 3, 2026
Earnings to watch: Zoetis (ZTS) reports Q3 results tomorrow
Animal health company Zoetis (NYSE:ZTS) will be reporting earnings this Thursday before market hours. Here’s what to look for. Zoetis missed analysts’ revenu...
Via StockStory · November 3, 2026
Viatris (VTRS) Q3 earnings report preview: what to look for
Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what investors should know. Viatris be...
Via StockStory · November 3, 2026
3 Dirt Cheap Dividend Stocks to Buy in November 2026fool.com
These high-yielding stocks pay up to 7.4% in dividends.
Via The Motley Fool · November 3, 2026
Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
Growing Demand for Next-Generation Therapies Is Putting Peptide Innovation at the Center of Healthcare's Biggest Growth Markets
By FN Media · Via GlobeNewswire · November 3, 2026
Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(OTCQX:RHHBY),(NYSE:NVO),(NASDAQ:VKTX),(NYSE:LLY) EQNX::TICKER_END
Via FinancialNewsMedia · November 3, 2026
Retatrutide Research Draws Attention in Costa Rica as Demand for Reliable Scientific Information Grows
San Jose, San Jose Province, Costa Rica, November 3, 2026 -- Interest in emerging metabolic research is bringing new attention to retatrutide in Costa Rica, as scientific developments surrounding this investigational compound generate discussion about the future of obesity and metabolic health research.
Via Press Release Distribution Service · November 3, 2026
Phibro Animal Health (PAHC) reports earnings tomorrow: what to expect
Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) will be announcing earnings results this Wednesday after market hours. Here’s what inv...
Via StockStory · November 2, 2026
Eli Lilly Stock: Is It Still a Buy at $1,400?fool.com
The company just released some incredible quarterly results, but its valuation is also fairly high.
Via The Motley Fool · November 2, 2026
Eli Lilly Just Delivered Another Blowout Quarter. Is This Unstoppable Growth Stock Still a Buy?fool.com
The drugmaker continues its impressive run.
Via The Motley Fool · November 2, 2026
GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?marketbeat.com
Compares the Roundhill GLP-1 & Weight Loss ETF (OZEM) and the newer REX Peptide ETF (PEPT), examining holdings, fees, and overlap as GLP-1 drug demand from Eli Lilly and Novo Nordisk continues to grow.
Via MarketBeat · November 2, 2026
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugsfool.com
The market for GLP-1 drugs is forecast to explode. It may be understated still.
Via The Motley Fool · November 2, 2026
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.fool.com
Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech.
Via The Motley Fool · November 2, 2026
Amneal (AMRX) Q3 earnings: what to expect
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what to expect. Amneal beat analys...
Via StockStory · November 2, 2026
What to expect from Pfizer’s (PFE) Q3 earnings
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before market open. Here’s what to expect. Pfizer beat analysts’ reven...
Via StockStory · November 1, 2026
Corcept (CORT) to report earnings tomorrow: here is what to expect
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday after market hours. Here’s what to look for. Corcept be...
Via StockStory · November 1, 2026
Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?marketbeat.com
Eli Lilly posted 39% YOY revenue growth in Q3 2026 on strong Mounjaro and Zepbound sales, raising full-year guidance even as Medicare's GLP-1 Bridge program pressures drug pricing.
Via MarketBeat · November 1, 2026
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?fool.com
Novo Nordisk is shifting its business model, with 2026 likely to represent an inflection point.
Via The Motley Fool · November 1, 2026
What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earnings
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Monday after market hours. Here’s what to expect. Jazz Pharmaceuticals be...
Via StockStory · October 31, 2026
After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?fool.com
Eli Lilly stock is trading at a record high.
Via The Motley Fool · October 31, 2026
Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030fool.com
GLP-1 weight loss drugs are propelling profits for some drugmakers like Eli Lilly.
Via The Motley Fool · October 31, 2026
2 Stocks Billionaires Can't Stop Buyingfool.com
Should you buy these stocks, too?
Via The Motley Fool · October 31, 2026
What Eli Lilly and Company (LLY) Said on Its Q3 Earnings Callmarketbeat.com
Eli Lilly and Company (NYSE:LLY) raised its full-year outlook after reporting third-quarter revenue growth of 39% from the prior-year period, driven primarily by demand for its Mounjaro and Zepbound incretin medicines and continued growth across international markets.
Chair and CEO Dave Ricks said
Via MarketBeat · October 30, 2026
OmniAb (OABI) Q3 2026 Earnings Call Transcriptfool.com
Revenue jumped to $4M as xPloration expands and Lilly partnership unlocks $3B in milestones.
Via The Motley Fool · October 30, 2026
Eli Lilly Is Now Worth as Much as Warren Buffett's Berkshire Hathaway. Can the Rally Keep Going?fool.com
Eli Lilly's business is heavily driven by one product, while Berkshire Hathaway is a diversified conglomerate.
Via The Motley Fool · October 30, 2026